Impact

For industrial and other user communities

​

• IVD developers

• Clinical laboratories

• Healthcare providers

• RM producers

• EQA providers 

• Drug developers

• Clinical researchers

• Regulators

For the metrology and scientific communities

​

• Improved NMI/DI capabilities for quantification of cancer genomic biomarkers, quantification of total nucleic acids, and detection of panels of genomic variants, demonstrated through inter-laboratory comparisons.
   

• Dissemination of case studies to advance the development of metrological frameworks for multi-analyte clinical genomic profiling.
   

• Submission of new RMP for quantification of cancer genomic biomarkers and SI-traceable RMs to JCTLM database.

For relevant standards

​

• support for existing standards

• input to the drafting of standards under development

• proposal for new standards 

Longer-term economic, social, and environmental impacts

​

• reduces diagnostic errors, preventing missed or incorrect diagnoses

• facilitates the administration of personalized treatments

• improve patient outcomes

• reduce healthcare costs

• growth in the European in vitro diagnostics and oncology therapeutics markets